<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND AND PURPOSE: <z:mp ids='MP_0002055'>Diabetes</z:mp> type 2 (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>) is associated with accelerated <z:hpo ids='HP_0001268'>cognitive decline</z:hpo> and structural brain abnormalities </plain></SENT>
<SENT sid="1" pm="."><plain>Macrovascular disease has been described as a determinant for brain MRI changes in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>, but little is known about the involvement of other <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>-related factors </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: Brain MRI was performed in 1043 participants (151 DM2) with symptomatic <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arterial disease</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>Brain volumes were obtained through automated segmentation </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: Patients with <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arterial disease</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> had more global and subcortical brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> (-1.20% brain/intracranial volume [95%CI -1.58 to -0.82], P&lt;0.0005 and 0.20% ventricular/intracranial volume [0.05 to 0.34], P&lt;0.01), larger WMH volumes (0.22 logtransformed volume [0.07 to 0.38], P&lt;0.005), and more lacunar <z:mpath ids='MPATH_124'>infarcts</z:mpath> (OR 1.75 [1.13 to 2.69], P&lt;0.01) than identical patients without <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> </plain></SENT>
<SENT sid="5" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>, high <z:chebi fb="105" ids="17234">glucose</z:chebi> levels (B-0.12% per mmol/L [-0.23 to -0.01], P&lt;0.05) and <z:mp ids='MP_0002055'>diabetes</z:mp> duration (B-0.05% per year [-0.10 to -0.001], P&lt;0.05) were associated with global brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> </plain></SENT>
<SENT sid="6" pm="."><plain>CONCLUSIONS: In patients with symptomatic <z:e sem="disease" ids="C0852949" disease_type="Disease or Syndrome" abbrv="">arterial disease</z:e>, <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e> has an added detrimental effect on the brain </plain></SENT>
<SENT sid="7" pm="."><plain>In patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">DM2</z:e>, <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and <z:mp ids='MP_0002055'>diabetes</z:mp> duration contribute to brain <z:mpath ids='MPATH_127'>atrophy</z:mpath> </plain></SENT>
</text></document>